These results underpin HIF-2α as a critical regulator of the anti-tumor immune response, suggesting HIF-2α blockade as a rational means to mitigate features of the immunosuppressive GBM microenvironment that complements and potentiates responsiveness to immunotherapies such as ICB [69]. This evidence concerns the gene EPAS1 and glioblastoma.